Is ADC Therapeutics SA (ADCT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 24.2% / 30% | 49.3% / 30% | 4.0% / 30% | 17.32% / 5% | ✗ NOT HALAL |
| DJIM | 24.2% / 33% | 49.3% / 33% | 4.0% / 33% | 17.32% / 5% | ✗ NOT HALAL |
| MSCI | 38.2% / 33% | 77.9% / 33% | 6.3% / 33% | 17.32% / 5% | ✗ NOT HALAL |
| S&P | 24.2% / 33% | 49.3% / 33% | 4.0% / 33% | 17.32% / 5% | ✗ NOT HALAL |
| FTSE | 38.2% / 33% | 77.9% / 33% | 6.3% / 50% | 17.32% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -32.2% | |
| Operating Margin | -69.3% | |
| Net Margin | -175.3% | |
| Return on Assets (ROA) | -20.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$141M |
| Free Cash Flow | -$141M |
| Total Debt | $117M |
| Current Ratio | 4.4 |
| Total Assets | $323M |
Price & Trading
| Last Close | $3.96 |
| 50-Day MA | $4.01 |
| 200-Day MA | $3.67 |
| Avg Volume | 806K |
| Beta | 2.0 |
|
52-Week Range
$1.05
| |
About ADC Therapeutics SA (ADCT)
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ADC Therapeutics SA (ADCT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ADC Therapeutics SA is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ADC Therapeutics SA's debt ratio?
ADC Therapeutics SA's debt ratio is 24.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 38.2%.
What are ADC Therapeutics SA's key financial metrics?
ADC Therapeutics SA has a market capitalization of $470M, and revenue of $81M. The company maintains a gross margin of -32.2% and a net margin of -175.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.